Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dexamethasone given orally Clear all
Active, not recruiting Phase 1 Interventional

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01562405
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACE-011, Lenalidomide, Dexamethasone, Pomalidomide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional

Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma

NCT00402766
View directory record Official record
Conditions
Mesothelioma
Interventions
Cisplatin, Imatinib Mesylate, Pemetrexed, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Sep 25, 2026, 8:45 PM EDT
Recruiting Phase 1 Interventional

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

NCT05581030
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Terminated Early Phase 1 Interventional

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

NCT01878708
View directory record Official record
Conditions
T-Cell Lymphoma, Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma
Interventions
PEG-L-asparaginase, Dexamethasone acetate
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 5, 2017 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

NCT05232825
View directory record Official record
Conditions
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Interventions
Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV, Diphenhydramine IV, Dexamethasone given orally, Desloratadine given orally
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Maitland, Florida • Tampa, Florida • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

NCT00440726
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia
Interventions
Bortezomib, Dexamethasone, PEG-asparaginase, Doxorubicin, Cytarabine, Methotrexate, Vincristine, Triple IT Therapy
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 25, 2026, 8:45 PM EDT
Active, not recruiting Phase 3 Interventional

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Talquetamab, Daratumumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
40
States / cities
Tucson, Arizona • Little Rock, Arkansas • Norwalk, Connecticut + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Withdrawn Phase 1 Interventional

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

NCT07082270
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography, Questionnaire Administration, Selvigaltin
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01355705
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Amrubicin, Lenalidomide, Dexamethasone, Aspirin, Pegfilgrastim
Drug
Lead sponsor
Michaela Liedtke
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

NCT00302003
View directory record Official record
Conditions
Childhood Favorable Prognosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma
Interventions
radiation therapy, doxorubicin hydrochloride, vincristine sulfate, prednisone, cyclophosphamide, ifosfamide, vinorelbine tartrate, dexamethasone, etoposide phosphate, cisplatin, cytarabine, filgrastim
Radiation · Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 25, 2026, 8:45 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

NCT00790842
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Lenalidomide, Dexamethasone, Anticoagulants
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 25, 2026, 8:45 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers

NCT00177255
View directory record Official record
Conditions
Cancer
Interventions
Docetaxel, Capecitabine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 25, 2026, 8:45 PM EDT
Recruiting Phase 2 Interventional

Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

NCT06533748
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Interventions
Dexamethasone, Vincristine, Inotuzumab, Blinatumomab, Dasatinib, IT MHA, Cyclophosphamide, Cytarabine, Methotrexate, 6-Mercaptopurine, Calaspargase, Daunorubicin, Thioguanine
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
3
States / cities
Charlotte, North Carolina • Tulsa, Oklahoma • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Selinexor Treatment of Refractory Myeloma

NCT02336815
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Selinexor, Dexamethasone
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00103285
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
3-Dimensional Conformal Radiation Therapy, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate
Radiation · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
5,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
210
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 25, 2026, 8:45 PM EDT
Recruiting Phase 2 Interventional

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

NCT05922501
View directory record Official record
Conditions
Relapsed Cancer, Refractory Multiple Myeloma, Multiple Myeloma
Interventions
Isatuximab, Belantamab mafodotin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Multiple Myeloma

NCT00002678
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, melphalan, prednisone
Drug
Lead sponsor
NCIC Clinical Trials Group
Network
Eligibility
18 Years to 120 Years
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2009
U.S. locations
1
States / cities
Duluth, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Sep 25, 2026, 8:45 PM EDT
Active, not recruiting Phase 2 Interventional

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

NCT04052880
View directory record Official record
Conditions
Newly Diagnosed Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Ixazomib
Drug
Lead sponsor
Larysa Sanchez
Other
Eligibility
70 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer

NCT01748942
View directory record Official record
Conditions
Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
Interventions
Dexamethasone, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Transoral Robotic Surgery
Drug · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 25, 2026, 8:45 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

NCT00430183
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, LHRH agonist, surgery
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
788 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
221
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Berkeley, California + 166 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional

Comparison of Different Combination Chemotherapy Regimens in Treating Children With Acute Lymphoblastic Leukemia

NCT00005945
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
3,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
116
States / cities
Phoenix, Arizona • Downey, California • Duarte, California + 92 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Use of Dexamethasone in Pediatric Asthma Exacerbations

NCT02192827
View directory record Official record
Conditions
Asthma
Interventions
Dexamethasone Sodium Phosphate Injection
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
2 Years to 20 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 25, 2026, 8:45 PM EDT
Completed Phase 1 Interventional

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

NCT02431208
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody, Daratumumab, Lenalidomide, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Sep 25, 2026, 8:45 PM EDT
Not listed Phase 4 Interventional

Ovulation Induction With Clomiphene Citrate and Dexamethasone

NCT01856062
View directory record Official record
Conditions
Infertility
Interventions
Placebo, Dexamethasone
Drug
Lead sponsor
San Antonio Military Medical Center
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2014 · Synced Sep 25, 2026, 8:45 PM EDT